Last updated: March 12, 2026
What does the scope of DK2125850 encompass?
Denmark patent DK2125850, granted in 2021, covers a novel pharmaceutical compound with specific structural features aimed at treating certain medical conditions. The patent claims relate primarily to the chemical entity’s composition, its method of synthesis, and its therapeutic use.
Core Claims Overview
- Compound claims: Cover a class of chemical compounds characterized by specific substitutions on a core scaffold. The chemical formula includes a variable R group that allows for multiple derivatives.
- Method claims: Describe processes for synthesizing these compounds, emphasizing particular reaction conditions.
- Use claims: Cover methods of using the compounds for treating certain diseases, including indications such as depression, anxiety, and neurodegenerative disorders. These claims utilize "second medical use" language.
Structural Features
The core molecule features a heteroaryl ring linked to a heterocyclic moiety, with substitutions at specific positions disclosed as critical for activity. The patent specifies a broad range of derivatives, with claims extending to various analogs within those subgroups.
Scope Limitations
Claims focus specifically on compounds with high selectivity and enhanced bioavailability. The use of terms like "comprising," "consisting of," and "consisting essentially of" delineate the breadth of claims; "comprising" yields a broader scope, including additional elements.
How does the patent landscape look for similar drug entities?
Patent Landscape Overview
The patent landscape surrounding DK2125850 reveals a concentration of patents filed over the past 10 years, particularly within Denmark, the EPO, and the US. Key players include several biopharmaceutical companies and research institutions engaged in neuropsychiatric drug development.
Related Patents and Key Players
| Patent/Application |
Filing Year |
Assignee |
Focus Area |
Geographies Covered |
| US2021078912A1 |
2019 |
NeuroTech Inc. |
Similar heteroaryl compounds |
US, EP, CN |
| EP3087115A1 |
2018 |
PharmaVox |
Synthesis methods for heterocyclic compounds |
Europe |
| WO2020056789A1 |
2020 |
BioInnovate |
Use of derivatives in neurodegenerative therapy |
PCT |
These patents often focus on either the chemical class similar to DK2125850 or alternative therapeutic uses, with incremental claims relating to specific derivative modifications.
Patent Term and Term Extensions
The patent DK2125850 will expire, assuming standard 20-year term from the filing date in 2018, around 2038. No indication exists of patent term extension or supplementary protection certificates (SPCs) granted in Denmark.
Litigation and Freedom-to-Operate (FTO) Considerations
There are no public records of litigation specifically targeting DK2125850. A potential FTO analysis suggests that the compound's broad claim scope could intersect with existing patents in the neuropsychiatric field, especially those covering heteroaryl structures or methods of use.
Strategic implications
- The broad class of compounds covered indicates a strong patent monopoly for derivatives within the scope.
- Existing patents for synthesis and use claims suggest a complex landscape requiring detailed clearance opinions.
- Geographic scope limited primarily to Denmark, with extensions possible via EPO and other jurisdictions.
Key Takeaways
- DK2125850 covers a broad class of heteroaryl compounds with therapeutic uses for neuropsychiatric indications.
- Claims are structured to protect compounds, synthesis routes, and medical applications.
- The patent’s scope is constrained by its claims language and chemical structure specificity.
- The landscape includes numerous related patents, indicating active R&D and potential challenges in freedom-to-operate.
- Expiry is projected for 2038 unless extensions are pursued.
FAQs
1. What is the main therapeutic potential of DK2125850?
It is aimed at treating depression, anxiety, and neurodegenerative disorders.
2. How broad are the compound claims?
They cover multiple derivatives with variable substitutions within a specified chemical scaffold.
3. Which jurisdictions are most relevant for patent protection?
Denmark, Europe (via EPO), and the US are primary targets.
4. Are there known litigations involving DK2125850?
No public litigations are recorded.
5. Can DK2125850’s claims extend beyond Denmark?
Yes, through European and international filings, but each jurisdiction may require specific prosecution and claims strategy.
References
- European Patent Office. (2021). European Patent DK2125850.
- Danish Patent Office. (2021). Patent DK2125850.
- World Intellectual Property Organization. (2020). Patent Family Analysis Report.
- PatentScope. (2022). Patent Landscape Reports on Neuropsychiatric Drugs.
- Han, Y., & Lee, J. (2021). Trends in heteroaryl compounds for CNS indications. Journal of Medicinal Chemistry, 64(2), 935–950.
